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Research
Correspondence Does Normal Left Atrial Size Really PredictNormal Stress Echocardiographic Results?To the Editor: Left atrial size has been shown to be an important
marker of cardiovascular risk burden, providing prognostic infor-
mation in different patient populations (1–3). Previously, a small
study published by Alsaileek et al. (4) suggested that a normal left
atrial volume index (LAVI) was highly predictive of a normal stress
echocardiogram. In that study, performed in 180 patients, no
patient with an LAVI 28 ml/m2 had stress-induced myocardial
schemia and only 5.7% had abnormal stress echocardiograms. Our
bjective was to evaluate the predictive value of LAVI for stress
chocardiographic abnormalities in a larger patient cohort under-
oing stress echocardiography, studied methodically over a 12-
onth period.
In 2006, all patients referred to the stress echocardiography
aboratory at Mayo Clinic (Rochester, Minnesota) also underwent
-dimensional and Doppler echocardiographic assessment of left
entricular diastolic function at baseline and at peak stress. Left
trial size was routinely measured at baseline. The biplane area-
ength method was used to calculate the left atrial volume, which
as indexed to body surface area. Stress echocardiography wasthen performed. Patients who did not give permission for their
data to be used for research purposes were excluded from the study,
as were patients who had at least moderate aortic or mitral stenosis
or at least moderately severe aortic or mitral regurgitation, chronic
atrial fibrillation, or dilated cardiomyopathy. Patients with normal
stress echocardiograms had normal left ventricular regional and
global systolic function at baseline and no stress-induced wall
motion abnormalities. Patients with abnormal stress echocardio-
grams had baseline regional wall motion abnormalities (fixed) or
stress-induced regional wall motion abnormalities (ischemic) or
both (mixed). Stress echocardiograms were positive for ischemia if
new or worsening regional wall motion abnormalities developed
with stress (ischemic or mixed). Potential associations between
LAVI measurements and abnormal and positive stress echocardio-
graphic results were examined using the chi-square test. Signifi-
cance was inferred at p  0.05.
A total of 7,336 patients were included in the study. Exercise
echocardiograms were performed in 56% of patients and dobut-
amine stress echocardiograms performed in 44%. The mean ageFigure 1 Stress Echocardiography Results of the Study Population According to LA Volume Index
p  0.0001 for the association between left atrial (LA) size and an abnormal (ischemic, mixed, or fixed) or positive (ischemic or mixed) stress echocardiographic result.
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June 11, 2013:2391–6was 63.3  13.3 years; 54% were men, 19% had diabetes, and
22% had known coronary artery disease, defined as a history of
myocardial infarction or prior coronary revascularization. The
stress echocardiograms were performed for evaluation of chest pain
or dyspnea in 55% of patients, preoperative assessment in 27%,
evaluation of known coronary artery disease in 10%, and other
reasons in 8%.
There was a significant association between the size of the left
atrium and abnormal stress echocardiographic results (Fig. 1). The
arger the left atrium, the greater the likelihood that the stress
chocardiogram would be abnormal (p  0.0001) or that there
ould be echocardiographic evidence of stress-induced ischemia
p  0.0001).
However, among patients with normal-sized atria (28
ml/m2), 23% had abnormal stress echocardiograms (ischemic,
ixed, or fixed) and 17% were positive for stress-induced
yocardial ischemia (ischemic or mixed). Even among patients
ith the smallest left atrial volumes (LAVI 20 ml/m2), 14%
were positive for stress-induced myocardial ischemia.
In this large population referred for clinically indicated stress
echocardiography, there was an association between the size of the
left atrium and stress echocardiographic findings in that the larger
the left atrium, the greater the likelihood that stress echocardio-
grams would be abnormal. However, patients who had normal left
atrial size also had abnormal or positive stress echocardiographic
results (23% and 17%, respectively) in this study. Thus, the
findings of a normal-sized left atrium on echocardiography should
not be used as a surrogate for predicting the absence of stress-
induced myocardial ischemia.
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Letters to the Editor
Simvastatin Effects
on Skeletal Muscle
Study Design and Validity
We read with great interest the report by Larsen et al. (1). In their
paper, they addressed a potential mechanism for statin-induced
myositis. This is a topic of clinical importance because muscle pain
is a common symptom for patients taking statins and the pain
often limits statin usage (2). Their physiological assessment of
individual patients was detailed and sophisticated. However, we
question their conclusion that simvastatin is the cause of the
muscle abnormalities they identified.
In their study, they compared Q10 content and maximal
oxidative phosphorylation (OXPHOS) capacity in 10 patients with
hypercholesterolemia who were taking simvastatin for at least 12
months with that in 9 healthy control volunteers with matched
age, weight, body mass index, fat percentage, and maximal oxygen
uptake. Our concern is that patients who take statins differ in many
clinical ways from healthy control individuals. These differences
between cases and controls are not likely to be balanced in the
matching, but they are likely to explain the difference in Q10
content and maximal OXPHOS capacity that the authors found.
For example, hyperlipidemia itself, preexisting metabolic syn-
drome, or other clinical conditions might alter coenzyme Q10
concentrations and cause the other physiological abnormalities
they identified. That such an explanation is likely is suggested by
the observation that patients with diabetes have altered Q10
concentrations (3). In the absence of a crossover study design or
selection of more appropriate case and control individuals, the
researchers’ conclusions do not seem valid.
The paper also suggested that the observed changes in coen-
zyme Q10 deficiency explained the myalgia, but this is speculative,
particularly because coenzyme Q10 supplementation has not been
consistently shown to alleviate statin-induced myopathy (4,5).
We applaud the authors for focusing their sophisticated phys-
ological methods on statin-associated myositis. We hope that they
nd others will apply these methods in patients using a more
ppropriate study design that will isolate any effects of long-term
tatin therapy from preexisting medical or other clinically relevant
onditions of patients (6).
Weeranun D. Bode, MD
oss J. Simpson, Jr., MD, PhD
University of North Carolina at Chapel Hill
01 Manning Drive
hapel Hill, North Carolina 27514
-mail: wdechyap@unch.unc.eduhttp://dx.doi.org/10.1016/j.jacc.2013.02.038
